Recruiting studies: Persistent Recurrent Or Metastatic Cervical Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical C
Phase 2 · 1 location(s) · Instituto Nacional de Cancer, Brazil · NCT06670911 Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3 · 5 location(s) · Lee's Pharmaceutical Limited · NCT06459687 Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Phase 2 · 1 location(s) · Zhongnan Hospital · NCT05817214 PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemother
Phase 2/Phase 3 · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07472153 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Phase 2/Phase 3 · 1 location(s) · Bio-Thera Solutions · NCT06123884 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · 155 location(s) · Merck Sharp & Dohme LLC · NCT07216703

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.